Clinical efficacy and tolerability of saperconazole for tinea of glabrous skin. A report on four cases.
In a randomized controlled trial three different treatment protocols with the new broad-spectrum peroral antifungal saperconazole were evaluated. The treatment regimens were as follows: 100 mg per day for 7 days, 200 mg per day for 7 days, 100 mg per day for 14 days. Of four assessable cases of dermatophytosis of glabrous skin treated with one of these three therapeutic regimens, one was cured. In this patient, however, the dermatophytosis relapsed after the end of the observation period, but due to a different microorganism. While partial improvement was seen in the other cases definite cure was not obtained. No adverse events were recorded.
Zienicke
H
H
Dermatologische Klinik und Poliklinik, Ludwigs-Maximilians-Universität München, Germany.
Korting
H C
HC
D000284:Administration, Oral; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D014005:Tinea / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D001393:Azoles; C060571:saperconazole